ES2922359T1 - Métodos para promover la producción de SCFA por la microbiota intestinal - Google Patents

Métodos para promover la producción de SCFA por la microbiota intestinal Download PDF

Info

Publication number
ES2922359T1
ES2922359T1 ES20796905T ES20796905T ES2922359T1 ES 2922359 T1 ES2922359 T1 ES 2922359T1 ES 20796905 T ES20796905 T ES 20796905T ES 20796905 T ES20796905 T ES 20796905T ES 2922359 T1 ES2922359 T1 ES 2922359T1
Authority
ES
Spain
Prior art keywords
subject
probiotic preparation
population
administration
acid bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES20796905T
Other languages
English (en)
Spanish (es)
Inventor
Barry Smith
Michael Butler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Multigerm UK Enterprises Ltd
Original Assignee
Multigerm UK Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multigerm UK Enterprises Ltd filed Critical Multigerm UK Enterprises Ltd
Publication of ES2922359T1 publication Critical patent/ES2922359T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pediatric Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
ES20796905T 2019-10-18 2020-10-16 Métodos para promover la producción de SCFA por la microbiota intestinal Pending ES2922359T1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201915144A GB201915144D0 (en) 2019-10-18 2019-10-18 Method of promoting SCFA production by gut microbiota
PCT/GB2020/052621 WO2021074649A2 (en) 2019-10-18 2020-10-16 Methods of promoting scfa production by gut microbiota

Publications (1)

Publication Number Publication Date
ES2922359T1 true ES2922359T1 (es) 2022-09-13

Family

ID=68728134

Family Applications (1)

Application Number Title Priority Date Filing Date
ES20796905T Pending ES2922359T1 (es) 2019-10-18 2020-10-16 Métodos para promover la producción de SCFA por la microbiota intestinal

Country Status (12)

Country Link
US (1) US12419921B2 (https=)
EP (1) EP4044830A2 (https=)
JP (2) JP7809339B2 (https=)
CN (2) CN114745970B (https=)
AU (1) AU2020368684B2 (https=)
BR (1) BR112022007413A2 (https=)
CA (1) CA3154083A1 (https=)
DE (1) DE20796905T1 (https=)
ES (1) ES2922359T1 (https=)
GB (1) GB201915144D0 (https=)
MX (1) MX2022004382A (https=)
WO (1) WO2021074649A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
CN113875975B (zh) * 2021-09-03 2023-06-30 许昌学院 一种利用小麦加工副产物制备后生元的发酵工艺
WO2024216281A1 (en) * 2023-04-14 2024-10-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment of circadian rhythm disorders
WO2025217259A1 (en) * 2024-04-10 2025-10-16 Postbiotics Plus Research Llc Use of postbiotics for treating or preventing disruptions of the gut-brain axis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6899872B1 (en) * 1995-11-27 2005-05-31 Standa Lab Sa Absorbable dietary composition for improving the biological balance of intestinal tract flora
GB2418431A (en) * 2004-09-27 2006-03-29 Multigerm Uk Entpr Ltd Metabolically active micro organisms and methods for their production
WO2011060123A1 (en) * 2009-11-12 2011-05-19 Nestec S.A. Nutritional composition for promoting gut microbiota balance and health
US8591412B2 (en) * 2009-11-18 2013-11-26 Nohands, Llc Method and system for preventing virus-related obesity and obesity related diseases
US9707207B2 (en) * 2010-05-26 2017-07-18 The United States Of America As Represented By The Department Of Veterans Affairs Method for diagnosing, preventing, and treating neurological diseases
US10086018B2 (en) * 2011-02-04 2018-10-02 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10512661B2 (en) 2011-02-04 2019-12-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
US10548761B2 (en) * 2011-02-04 2020-02-04 Joseph E. Kovarik Method and system for reducing the likelihood of colorectal cancer in a human being
US10842834B2 (en) 2016-01-06 2020-11-24 Joseph E. Kovarik Method and system for reducing the likelihood of developing liver cancer in an individual diagnosed with non-alcoholic fatty liver disease
DK3329927T3 (da) * 2011-11-16 2023-12-11 Multigerm Uk Entpr Ltd IBS-behandling med probiotika
GB201219873D0 (en) * 2012-11-05 2012-12-19 Multigerm Uk Entpr Ltd Diverticulitis treatment
US8889633B2 (en) * 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
WO2015159125A1 (en) * 2014-04-15 2015-10-22 Compagnie Gervais Danone Use of lactobacillus rhamnosus for promoting recovery of the intestinal microbiota diversity after antibiotic dysbiosis
EP3639834B1 (en) * 2016-02-04 2023-07-12 Universiteit Gent Use of microbial communities for human and animal health
US10055534B2 (en) * 2016-03-17 2018-08-21 Applied Materials Israel Ltd. System and method for design based inspection
PL3443071T3 (pl) * 2016-04-11 2022-03-28 Wageningen Universiteit Nowe gatunki bakterii
US20180357375A1 (en) 2017-04-04 2018-12-13 Whole Biome Inc. Methods and compositions for determining metabolic maps
US11730749B2 (en) 2017-05-05 2023-08-22 Plexus Worldwide, Llc Compositions and methods for improving gut health
AU2018313765A1 (en) 2017-08-07 2020-02-27 Finch Therapeutics, Inc. Compositions and methods for decolonizing antibotic-resistant bacteria in the gut
AU2019216129B2 (en) * 2018-02-02 2022-03-17 Kobiolabs, Inc. Lactobacillus plantarum KBL396 strain and use thereof
GB201915144D0 (en) * 2019-10-18 2019-12-04 Multigerm Uk Entpr Ltd Method of promoting SCFA production by gut microbiota
FR3136482A1 (fr) * 2021-08-01 2023-12-15 Snipr Biome Aps Ingenierie du microbiote

Also Published As

Publication number Publication date
GB201915144D0 (en) 2019-12-04
US20230053778A1 (en) 2023-02-23
MX2022004382A (es) 2022-08-25
DE20796905T1 (de) 2022-11-24
AU2020368684A1 (en) 2022-05-19
CN114745970A (zh) 2022-07-12
CA3154083A1 (en) 2021-04-22
JP2025163045A (ja) 2025-10-28
WO2021074649A2 (en) 2021-04-22
JP2022553017A (ja) 2022-12-21
BR112022007413A2 (pt) 2022-07-05
CN118593548A (zh) 2024-09-06
AU2020368684B2 (en) 2026-02-12
JP7809339B2 (ja) 2026-02-02
US12419921B2 (en) 2025-09-23
WO2021074649A3 (en) 2021-07-22
EP4044830A2 (en) 2022-08-24
CN114745970B (zh) 2024-06-21

Similar Documents

Publication Publication Date Title
ES2922359T1 (es) Métodos para promover la producción de SCFA por la microbiota intestinal
Kanbay et al. The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus
Janssen et al. The role of the gut microbiota in metabolic health
Haque et al. Intestinal microbiota in liver disease
ES2908310T3 (es) Akkermansia pasteurizada para promover la pérdida de peso
Lau et al. Gut microbiota: association with NAFLD and metabolic disturbances
ES2764785T3 (es) Bacteroides cect 7771 y su uso en la prevención y tratamiento de sobrepeso, obesidad y alteraciones metabólicas e inmunológicas
Gyriki et al. The gut microbiota and aging: interactions, implications, and interventions
Huang et al. Bile acids elevated by high-fat feeding induce endoplasmic reticulum stress in intestinal stem cells and contribute to mucosal barrier damage
BR112012016982B8 (pt) bactéria de ácido lático recombinante de grau alimentício e composição terapêutica
US10137108B2 (en) Nutritional composition useful in the treatment of IBD patients
CO6410310A2 (es) Composiciones que comprenden componentes probióticos y prebióticos y sales minerales, con lactoferrina
JP2022553017A5 (https=)
PH12016501952A1 (en) Nutritional compositions directed to subjects having cow`s milk protein allergies
McClave Nutrition support in acute pancreatitis
EA201991301A1 (ru) Урогенитальная композиция для медицинского устройства на основе подходящих биохимических композиций для стабилизации кислотности и редокс-состояния вагинальной жидкости
MY191961A (en) Nutritional composition for gastrointestinal environment to provide improved microbiome and metabolic profile
Heinzerling et al. Intestinal alkaline phosphatase is protective to the preterm rat pup intestine
Shaikh et al. Metabiotics and their health benefits
HRP20230639T1 (hr) Pripravak koji sadrži lactobacillus reuteri i citrat za medicinsku primjenu
RU2015139356A (ru) Низкобуферные питательные композиции и их применение
RU2013134133A (ru) Применение содержащих лактоферрин питательных композиций при поддержании устойчивости к заболеваниям и состояниям
Schultz et al. Escherichia coli Nissle 1917
JP2019170335A5 (https=)
Jiménez-González et al. Assessing the therapeutic potential of fecal microbiota transplantation in steatotic liver disease: Current insights and future pathways